<DOC>
	<DOCNO>NCT00239577</DOCNO>
	<brief_summary>This descriptive study evaluate safety immunogenicity 5 different formulation WRAIR dengue vaccine compare placebo .</brief_summary>
	<brief_title>A Trial Walter Reed Army Institute Research ( WRAIR ) Live Attenuated Virus Tetravalent Dengue Vaccine Healthy US Adults</brief_title>
	<detailed_description>Subjects randomize one 6 group . One group receive placebo vaccine others receive one 5 different dengue vaccine formation . Each subject receive two dos six month apart . Study subject elect participate mosquito transmissibility component study undergo mosquito feeding two assign follow-up visit vaccine dose 1 . All subject 11 venipuncture 11 visit ( i.e. , screen plus 10 study visit ) period nine month .</detailed_description>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion : Healthy male female adult 1845 year time vaccination Free obvious health problem establish medical history physical examination enter study Written inform consent obtain subject Able read Subject Information Sheet Consent Form Subjects investigator believe comply requirement protocol Females must nonchildbearing potential , , childbearing potential , must abstinent use adequate contraceptive precaution define protocol 30 day prior vaccination , negative pregnancy test within 48 hour prior vaccination must agree continue precaution 60 day completion vaccination series Exclusion : History : recurrent migraine headache neurological behavioral disorder seizure drug abuse alcohol consumption ( 2 drink per day ) allergic disease/reaction likely exacerbate vaccine urticaria relate mosquito bite require medical attention Acute chronic , clinically significant pulmonary , cardiovascular , hepatic , renal , hematologic endocrine functional defect Any confirm suspected immunosuppressive immunodeficient condition ; Seropositive HBsAg , antiHCV antiHIV Acute disease time enrollment Chronic hepatomegaly splenomegaly Use investigational nonregistered drug vaccine within 30 day precede study plan use Planned administration vaccine foreseen study protocol 30 day Â±each vaccine dose Planned move study Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug administration immunoglobulins and/or blood product , within 90 day precede first dose plan administration study period Any chronic systemic drug therapy continue study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Dengue infection</keyword>
</DOC>